"Zepbound Surpasses Wegovy in US Prescriptions for Weight-Loss"

Eli Lilly's weight-loss drug Zepbound surpassed Novo Nordisk's rival obesity medicine Wegovy in new U.S. prescriptions for the first time, with 77,590 new prescriptions compared to Wegovy's 6,000 fewer. The competition reflects the growing market for weight-loss drugs, with demand outpacing supplies and analysts predicting a market worth at least $100 billion by the end of the decade. Both Zepbound and Wegovy belong to a class of drugs called GLP-1 agonists, originally developed for type 2 diabetes, and are expected to surpass cancer immunotherapies as the best-selling medicines. GlobalData forecasts the market for these medicines to reach $105 billion by 2029, with Novo Nordisk capturing more than half of that.